T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.
复制标题
DOI：
10.2217/imt.09.61
复制
发表时间：
2010-01
期刊：
影响因子：
2.8
通讯作者：
Rostami A
中科院分区：
文献类型：
--
作者：
O'Brien K;Gran B;Rostami A
多发性硬化症（MS）被认为是T细胞介导的自身免疫性疾病的原因之一是在某些啮齿动物和灵长类动物中可以通过用髓鞘抗原免疫诱导类似的实验性疾病，导致CNS中T细胞介导的炎性脱髓鞘。此外，大多数（如果不是所有）可用于MS的药理学治疗对T细胞具有生物活性。在这篇文章中，我们回顾了基于T细胞的免疫疗法的原理以及当前和新型治疗对T细胞功能的具体作用。对于许可和创新药物，我们还讨论了对其他免疫细胞类型的生物作用。最后，我们提供了一个简短的观点，在不久的将来MS免疫疗法的使用预期的变化。
One of the reasons multiple sclerosis (MS) has been considered a T-cell mediated autoimmune disease is that a similar experimental disease can be induced in certain rodents and primates by immunization with myelin antigens, leading to T-cell-mediated inflammatory demyelination in the CNS. In addition, most if not all pharmacological treatments available for MS are biologically active on T cells. In this article we review the principles of T-cell-based immunotherapies and the specific actions of current and novel treatments on T-cell functions, when these are known. For both licensed and innovative agents, we also discuss biological actions on other immune cell types. Finally, we offer a brief perspective on expected changes in the use of MS immunotherapies in the near future.